Colin C Pritchard

List of Publications by Citations

97 papers	10,127 citations	36 h-index	100 g-index
107 ext. papers	12,778 ext. citations	9.2 avg, IF	6.05 L-index

#	Paper	IF	Citations
97	Integrative clinical genomics of advanced prostate cancer. *Cell*, **2015**, 161, 1215-1228	56.2	1765
96	MicroRNA profiling: approaches and considerations. *Nature Reviews Genetics*, **2012**, 13, 358-69	30.1	1185
95	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 443-53	59.2	791
94	Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. *Cancer Prevention Research*, **2012**, 5, 492-497	3.2	675
93	Classification and characterization of microsatellite instability across 18 cancer types. *Nature Medicine*, **2016**, 22, 1342-1350	50.5	432
92	The long tail of oncogenic drivers in prostate cancer. *Nature Genetics*, **2018**, 50, 645-651	36.3	380
91	Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. *JAMA Oncology*, **2017**, 3, 464-471	13.4	335
90	Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. *Gastroenterology*, **2014**, 147, 1308-1316.e1	13.3	269
89	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. *Genome Research*, **2015**, 25, 305-15	9.7	252
88	Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. *Nature Genetics*, **2015**, 47, 180-5	36.3	239
87	Microsatellite instability detection by next generation sequencing. *Clinical Chemistry*, **2014**, 60, 1192-9	5.5	237
86	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. *Cancer Discovery*, **2018**, 8, 730-749	24.4	235
85	Colorectal cancer molecular biology moves into clinical practice. *Gut*, **2011**, 60, 116-29	19.2	235
84	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. *Journal of Molecular Diagnostics*, **2014**, 16, 56-67	5.1	203
83	Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. *Nature Communications*, **2014**, 5, 4988	17.4	182
82	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. *European Urology*, **2016**, 69, 992-5	10.2	175
81	ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. *Journal of Molecular Diagnostics*, **2012**, 14, 357-66	5.1	163

80	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of Reversion Mutations Associated with Resistance to PARP Inhibitors. *Cancer Discovery*, **2017**, 7, 999-1005	24.4	158
79	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *European Urology*, **2020**, 77, 508-547	10.2	155
78	DNA Repair in Prostate Cancer: Biology and Clinical Implications. *European Urology*, **2017**, 71, 417-425	10.2	132
77	-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. *JCI Insight*, **2016**, 1,	9.9	90
76	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. *Cancer*, **2016**, 122, 304-11	6.4	89
75	Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. *JAMA Oncology*, **2018**, 4, 806-813	13.4	85
74	Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. *Haematologica*, **2015**, 100, 42-8	6.6	81
73	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *Journal of Clinical Oncology*, **2020**, 38, 2798-2811	2.2	80
72	MSH2 Loss in Primary Prostate Cancer. *Clinical Cancer Research*, **2017**, 23, 6863-6874	12.9	78
71	Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. *Haematologica*, **2016**, 101, 1343-1350	6.6	74
70	Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. *JAMA Oncology*, **2016**, 2, 370-2	13.4	68
69	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. *Clinical Cancer Research*, **2017**, 23, 1263-1273	12.9	67
68	Improving performance of multigene panels for genomic analysis of cancer predisposition. *Genetics in Medicine*, **2016**, 18, 974-81	8.1	60
67	Detection of gene rearrangements in targeted clinical next-generation sequencing. *Journal of Molecular Diagnostics*, **2014**, 16, 405-17	5.1	59
66	Microsatellite instability in prostate cancer by PCR or next-generation sequencing **2018**, 6, 29		58
65	Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. *Cell Reports*, **2020**, 31, 107669	10.6	55
64	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. *European Urology*, **2019**, 75, 184-192	10.2	49
63	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. *Oncotarget*, **2016**, 7, 82504-82510	3.3	47

62	Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. *Human Pathology*, **2014**, 45, 1563-71	3.7	36
61	Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing. *Clinical Chemistry*, **2018**, 64, 950-958	5.5	34
60	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. *JAMA Oncology*, **2021**, 7, 107-110	13.4	34
59	MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing. *Journal of Molecular Diagnostics*, **2015**, 17, 705-14	5.1	33
58	Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. *Modern Pathology*, **2018**, 31, 1891-1900	9.8	32
57	Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome. *Journal of Medical Genetics*, **2019**, 56, 462-470	5.8	31
56	CADD score has limited clinical validity for the identification of pathogenic variants in noncoding regions in a hereditary cancer panel. *Genetics in Medicine*, **2016**, 18, 1269-1275	8.1	30
55	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. *PLoS ONE*, **2020**, 15, e0233260	3.7	29
54	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. *Gastroenterology*, **2016**, 151, 440-447.e1	13.3	29
53	A mosaic PTEN mutation causing Cowden syndrome identified by deep sequencing. *Genetics in Medicine*, **2013**, 15, 1004-7	8.1	26
52	-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. *JCO Precision Oncology*, **2020**, 4, 382-392	3.6	26
51	Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance. *Gastroenterology*, **2017**, 152, 1876-1880.e1	13.3	25
50	COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. *BMC Clinical Pathology*, **2010**, 10, 6	3	25
49	Initiation of universal tumor screening for Lynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice. *Cancer*, **2016**, 122, 393-401	6.4	23
48	Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in Mutation Carriers. *Clinical Cancer Research*, **2019**, 25, 1786-1794	12.9	23
47	The effects of genomic germline variant reclassification on clinical cancer care. *Oncotarget*, **2019**, 10, 417-423	3.3	22
46	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. *American Journal of Surgical Pathology*, **2020**, 44, e15-e29	6.7	21
45	Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. *Journal of Pathology*, **2019**, 249, 79-89	9.4	20

44	Lynch Syndrome: From Screening to Diagnosis to Treatment in the Era of Modern Molecular Oncology. *Annual Review of Genomics and Human Genetics*, **2019**, 20, 293-307	9.7	19
43	Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome. *Human Pathology*, **2018**, 78, 125-130	3.7	19
42	Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. *American Journal of Human Genetics*, **2018**, 103, 19-29	11	19
41	Prostate Cancer Screening in a New Era of Genetics. *Clinical Genitourinary Cancer*, **2017**, 15, 625-628	3.3	19
40	Family-Specific Variants and the Limits of Human Genetics. *Trends in Molecular Medicine*, **2016**, 22, 925-934	14.5	18
39	A novel disease-causing synonymous exonic mutation in affecting RNA splicing. *Blood*, **2018**, 132, 1211-1215	11	17
38	A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 8-17	7.3	17
37	Characterization of splice-altering mutations in inherited predisposition to cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**,	11.5	17
36	Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots". *Genetics in Medicine*, **2020**, 22, 825-830	8.1	14
35	A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. *Oncotarget*, **2016**, 7, 52888-52899	3.3	14
34	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. *Prostate*, **2016**, 76, 1303-11	4.2	14
33	Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients. *American Journal of Medical Genetics, Part A*, **2018**, 176, 2301-2308	2.5	13
32	Werner syndrome through the lens of tissue and tumour genomics. *Scientific Reports*, **2016**, 6, 32038	4.9	13
31	Glandular differentiation in dedifferentiated chondrosarcoma: molecular evidence of a rare phenomenon. *Human Pathology*, **2015**, 46, 1398-404	3.7	12
30	Mismatch repair enzyme expression in primary and castrate resistant prostate cancer. *Asian Journal of Urology*, **2016**, 3, 223-228	2.7	12
29	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. *Oncologist*, **2021**, 26, e270-e278	5.7	12
28	Deep sequencing with intronic capture enables identification of an APC exon 10 inversion in a patient with polyposis. *Genetics in Medicine*, **2014**, 16, 783-6	8.1	11
27	Germline variants drive myelodysplastic syndrome in young adults. *Leukemia*, **2021**, 35, 2439-2444	10.7	11

26	DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223. *Clinical Genitourinary Cancer*, **2018**, 16, 106-110	3.3	11
25	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. *Prostate*, **2019**, 79, 701-708	4.2	9
24	Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. *JAMA Oncology*, **2021**,	13.4	8
23	MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas. *Human Pathology*, **2020**, 96, 104-111	3.7	7
22	Jumping translocations in myelodysplastic syndromes. *Cancer Genetics*, **2016**, 209, 395-402	2.3	7
21	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. *Gynecologic Oncology*, **2021**, 160, 161-168	4.9	7
20	Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness. *Canadian Journal of Urology*, **2019**, 26, 24-26	0.8	7
19	Genomic and Clinicopathologic Characterization of -deficient Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 4869-4881	12.9	6
18	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. *JCO Precision Oncology*, **2021**, 5,	3.6	6
17	DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features. *Histopathology*, **2019**, 74, 836-843	7.3	6
16	Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations. *Pediatric and Developmental Pathology*, **2018**, 21, 380-388	2.2	5
15	Applying Ancestry and Sex Computation as a Quality Control Tool in Targeted Next-Generation Sequencing. *American Journal of Clinical Pathology*, **2016**, 145, 308-15	1.9	5
14	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. *Prostate*, **2017**, 77, 123-144	4.2	4
13	Inherited TP53 Variants and Risk of Prostate Cancer. *European Urology*, **2021**,	10.2	4
12	Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. *JNCI Cancer Spectrum*, **2020**, 4, pkaa054	4.6	4
11	Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome. *Journal of Genetic Counseling*, **2016**, 25, 515-9	2.5	3
10	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 358-369	7.1	3
9	Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 1150-1155	7.3	3

8	Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog. *Journal of Molecular Diagnostics*, **2018**, 20, 512-521	5.1	3
7	Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. *Clinical Cancer Research*, **2021**,	12.9	2
6	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. *European Urology*, **2022**,	10.2	2
5	USP15 deubiquitinase safeguards hematopoiesis and genome integrity in hematopoietic stem cells and leukemia cells		1
4	The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre international retreat. *Canadian Urological Association Journal*, **2021**, 15, E623-E629	1.2	0
3	Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.. *JCO Precision Oncology*, **2022**, 6, e2100280	3.6	0
2	Detection of Mutations in Inherited Bone Marrow Failure and Myelodysplastic Syndrome Genes Using Genomic Capture and Massively Parallel Sequencing in Clinical Diagnostics. *Blood*, **2016**, 128, 1507-1507	2.2	
1	Postmortem Somatic Sequencing of Tumors From Patients With Suspected Lynch Syndrome Has Clinical Utility for Surviving Relatives. *JCO Precision Oncology*, **2018**, 2,	3.6	